Glycemic Benefit of Insulin Degludec/Insulin Aspart Compared to Basal Insulin in Type 2 Diabetes Mellitus Associated with Impaired Glucagon-Like Peptide-1 Response: A Randomized Crossover Trial
Diabetes & Metabolism Journal · 2025
DOI: 10.4093/dmj.2024.0741 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes & Metabolism Journal, 2025. Verfasst von Han Na Jang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin, Long-Acting, Hypoglycemic Agents, Glucagon-Like Peptide 1. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
- Department of Internal Medicine, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Korea.
- Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea.
- Institute of Neuroscience, National Research Council, Padova, Italy.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
- Novo Nordisk
Zitieren
APA
Jang, H. N., Hong, E. S., Yang, Y. S., Lee, S. O., Jang, M. J., Mari, A., Kwak, S. H., Park, K. S., Jang, H. C., & Jung, H. S. (2025). Glycemic Benefit of Insulin Degludec/Insulin Aspart Compared to Basal Insulin in Type 2 Diabetes Mellitus Associated with Impaired Glucagon-Like Peptide-1 Response: A Randomized Crossover Trial. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2024.0741
Vancouver
Jang HN, Hong ES, Yang YS, Lee SO, Jang MJ, Mari A, et al. Glycemic Benefit of Insulin Degludec/Insulin Aspart Compared to Basal Insulin in Type 2 Diabetes Mellitus Associated with Impaired Glucagon-Like Peptide-1 Response: A Randomized Crossover Trial. Diabetes & Metabolism Journal. 2025. doi:10.4093/dmj.2024.0741
BibTeX
@article{Jang2025,
author = {Jang, Han Na and Hong, Eun Shil and Yang, Ye Seul and Lee, Seong Ok and Jang, Myoung-Jin and Mari, Andrea and Kwak, Soo Heon and Park, Kyong Soo and Jang, Hak Chul and Jung, Hye Seung},
title = {Glycemic Benefit of Insulin Degludec/Insulin Aspart Compared to Basal Insulin in Type 2 Diabetes Mellitus Associated with Impaired Glucagon-Like Peptide-1 Response: A Randomized Crossover Trial},
journal = {Diabetes & Metabolism Journal},
year = {2025},
doi = {10.4093/dmj.2024.0741}
}
EUVIMED